SVC112
Cancer (unspecified solid tumors)
PreclinicalActive
Key Facts
About SuviCa
SuviCa is a preclinical-stage oncology biotech developing small molecule protein synthesis inhibitors designed to overcome resistance to standard cancer treatments. The company's lead asset, SVC112, is in preclinical development and targets a unique mechanism to prevent tumor regrowth post-therapy. Led by an experienced management team with a strong track record in biotech, including CEO Judy Hemberger, PhD, MBA, SuviCa leverages academic research from its co-founder and CSO, Dr. Tin Tin Su. The company has secured non-dilutive funding through SBIR grants and is positioned to pursue combination therapy opportunities in oncology.
View full company profileTherapeutic Areas
Other Cancer (unspecified solid tumors) Drugs
| Drug | Company | Phase |
|---|---|---|
| Ateganosine (THIO) | MAIA Biotechnology | Phase 2 |